PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 142 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2018. The put-call ratio across all filers is 1.87 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $466,000 | -23.7% | 66,530 | 0.0% | 0.00% | – |
| Q2 2021 | $611,000 | -17.1% | 66,530 | -12.3% | 0.00% | – |
| Q1 2021 | $737,000 | -5.3% | 75,830 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $778,000 | +1.7% | 75,830 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $765,000 | -0.8% | 75,830 | +2.6% | 0.00% | 0.0% |
| Q2 2020 | $771,000 | +53.6% | 73,930 | +24.2% | 0.00% | 0.0% |
| Q1 2020 | $502,000 | -3.6% | 59,530 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $521,000 | -14.7% | 59,530 | +4.9% | 0.00% | 0.0% |
| Q3 2019 | $611,000 | -15.4% | 56,730 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $722,000 | -66.5% | 56,730 | +2.0% | 0.00% | -50.0% |
| Q1 2019 | $2,153,000 | +97.2% | 55,630 | +3.3% | 0.00% | +100.0% |
| Q4 2018 | $1,092,000 | -54.1% | 53,830 | +3.7% | 0.00% | -66.7% |
| Q3 2018 | $2,381,000 | -22.5% | 51,930 | 0.0% | 0.00% | -25.0% |
| Q2 2018 | $3,072,000 | -13.1% | 51,930 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $3,534,000 | -29.5% | 51,930 | +2.4% | 0.00% | -20.0% |
| Q4 2017 | $5,015,000 | -14.6% | 50,730 | +3.5% | 0.01% | -28.6% |
| Q3 2017 | $5,871,000 | +37.0% | 49,030 | 0.0% | 0.01% | +40.0% |
| Q2 2017 | $4,285,000 | +110.5% | 49,030 | -10.4% | 0.01% | +66.7% |
| Q1 2017 | $2,036,000 | +23.7% | 54,730 | +2.1% | 0.00% | 0.0% |
| Q4 2016 | $1,646,000 | -43.7% | 53,630 | +22.9% | 0.00% | -40.0% |
| Q3 2016 | $2,925,000 | +117.6% | 43,630 | -3.3% | 0.01% | +150.0% |
| Q2 2016 | $1,344,000 | +5.1% | 45,130 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $1,279,000 | -54.7% | 45,130 | +25.3% | 0.00% | -71.4% |
| Q4 2015 | $2,825,000 | -27.4% | 36,030 | -30.2% | 0.01% | -30.0% |
| Q3 2015 | $3,889,000 | -28.2% | 51,600 | +11.2% | 0.01% | -28.6% |
| Q2 2015 | $5,417,000 | -24.5% | 46,400 | +52.6% | 0.01% | -26.3% |
| Q1 2015 | $7,178,000 | +26.4% | 30,400 | +1.3% | 0.02% | -9.5% |
| Q4 2014 | $5,678,000 | -13.1% | 30,000 | +9.5% | 0.02% | -16.0% |
| Q3 2014 | $6,537,000 | +255.1% | 27,400 | -1.8% | 0.02% | +257.1% |
| Q2 2014 | $1,841,000 | – | 27,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |